Motloch, L.J.,
Larbig, R.,
Darabi, T.,
Reda, S.,
Motloch, K.A.,
Wernly, B.,
Lichtenauer, M.,
Gebing, T.,
Schwaiger, A.,
Zagidullin, N.,
Wolny, M.,
Hoppe, U.C. (2017) clinical symptoms. Hyperpolarization-activated cyclic nucleotide channel 4 (HCN4) underlies the pacemaker
Yunusbaeva, M.,
Borodina, L.,
Alekseev, P.,
Davydov, R.,
Sharipov, R.,
Bilalov, F.,
Yunusbayev, B. (2019) recommendations. Altogether, 369 patients completed the full course of chemotherapy.
Clinical characteristics